MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, RPTX had $5,169K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$5,169K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss for the period
3,258 -46,787
Share-based compensation expense
1,409 6,047
Depreciation expense
72 2,222
Non-cash lease expense
299 1,295
Foreign exchange gain
-39 117
Net accretion of marketable securities
480 1,006
Gain on sale of technology and other assets
130 5,666
Gain on termination of collaboration agreement
3,257 -
Impairment loss on rou asset
330 -
Prepaid expenses
1,052 -3,006
Other current receivables
-1,463 -67
Other non-current assets
0 -179
Deferred collaboration cost recovery
-3,257
Accounts payable
-2,667 382
Accrued expenses and other current liabilities
-2,223 -7,652
Operating lease liability, current portion
-302 -1,223
Income taxes
9,149 609
Operating lease liability, net of current portion
0 -88
Deferred revenue
0 0
Net cash used in operating activities
2,651 -45,475
Proceeds from sale of technology and other assets
0 1,000
Proceeds from maturities of marketable securities
10,150 73,662
Purchase of marketable securities
7,613 46,456
Net cash provided by investing activities
2,537 28,206
Proceeds from exercise of stock options
0 0
Proceeds from issuance of common stock under the 2020 employee share purchase plan
30 79
Net cash provided by financing activities
30 79
Effect of exchange rate fluctuations on cash held
-49 129
Net decrease in cash and cash equivalents
5,169 -17,061
Cash and cash equivalents at beginning of period
84,717 -
Cash and cash equivalents at end of period
72,825 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Repare Therapeutics Inc. (RPTX)

Repare Therapeutics Inc. (RPTX)